Moderna Inc

NASDAQ:MRNA   3:59:59 PM EDT
454.44
+13.72 (+3.11%)
4:43:07 PM EDT: $454.49 +0.05 (+0.01%)
Products, Strategic Combinations

Moderna To Develop mRNA Therapeutic For Ultra-Rare Disease With Institute For Life Changing Medicines

Published: 09/07/2021 12:51 GMT
Moderna Inc (MRNA) - Moderna and the Institute for Life Changing Medicines Announce a New Collaboration to Develop an Mrna Therapeutic for Ultra-rare Disease, Crigler-najjar Syndrome Type 1.
Moderna Inc - Moderna Will License Mrna-3351 to Ilcm With No Upfront Fees, and Without Any Downstream Payments.
Moderna Inc - Ilcm Will Be Responsible for the Clinical Development of Mrna-3351.
Moderna Inc - Ilcm Plans to Initiate Clinical Studies of Mrna-3351 in 2022.